Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8895520
SERIAL NO

13281827

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method of treatment of a human patient suffering from myeloid neoplasias, includes administrating a therapeutically effective amount of 5-aminoimidazole-4-carboxamide (acadesine), acadesine precursors or acadesine derivatives.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)101 RUE DE TOLBIAC PARIS CEDEX 13 75654
CENTRE HOSPITALIER UNIVERSITAIRE DE NICE4 AVENUE REINE VICTORIA BP1179 F-06003 NICE CEDEX 1 FRANCE
UNIVERSITE NICE SOPHIA ANTIPOLIS28 AVENUE VALROSE NICE F-06103

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Auberger, Patrick Nice, FR 6 0
Cluzeau, Thomas Nice, FR 2 0
Robert, Guillaume Nice, FR 6 60

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 25, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00